Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

罗视佳 - NMPA Drug Approval Details

Approvals/NMPA/Faricimab Injection

Approved

生物制品

Faricimab Injection

Roche Pharma (Schweiz) AG🇨🇳 National Medical Products Administration

Approval Date: Dec 13, 2023
Approval ID: 8VgmlD6WVtR
Company: Roche Pharma (Schweiz) AG
Type: 生物制品

Approval Details

Approval Id: 8VgmlD6WVtR
Approval Number: 国药准字SJ20230018
Generic Name: 法瑞西单抗注射液
Generic Name En: Faricimab Injection
Trade Name: 罗视佳
Drug Type: 生物制品
Dosage Form: 眼用制剂
Strength: 0.05ml（6mg）/瓶
Reg Date: 2023-12-13
Expired Date: 2028-12-12
Company Name: Roche Pharma (Schweiz) AG
Production Company Name: F. Hoffmann-La Roche AG
Company Detail Path: /organization/roche-pharma-schweiz-ag
Production Company Detail Path: /organization/f-hoffmann-la-roche-ag

Approved

Quick Info

Agency

NMPA

Country

🇨🇳

Approval Date

Dec 13, 2023

Approval ID

8VgmlD6WVtR

Type

生物制品

Back to NMPA Approvals